176 related articles for article (PubMed ID: 34694916)
1. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons.
Chappidi MR; Yang H; Meng MV; Bivalacqua TJ; Daneshmand S; Holzbeierlein JM; Kaimakliotis HZ; Konety B; Liao JC; Pohar K; Steinberg GD; Taylor JM; Tyson MD; Willard B; Lotan Y; Porten SP; Kates M
J Urol; 2022 Mar; 207(3):534-540. PubMed ID: 34694916
[TBL] [Abstract][Full Text] [Related]
2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Shore ND; Gavaghan MB
Urol Oncol; 2023 Apr; 41(4):207.e9-207.e16. PubMed ID: 36564259
[TBL] [Abstract][Full Text] [Related]
4. Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.
Daneshmand S; Bazargani ST; Bivalacqua TJ; Holzbeierlein JM; Willard B; Taylor JM; Liao JC; Pohar K; Tierney J; Konety B;
Urol Oncol; 2018 Aug; 36(8):361.e1-361.e6. PubMed ID: 29859728
[TBL] [Abstract][Full Text] [Related]
5. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
[TBL] [Abstract][Full Text] [Related]
7. Blue light cystoscopy with hexylaminolevulinate: Our 7 years experience.
Lacetera V; Cantoro U; Montesi L; Cantoro D; Cervelli B; Cicetti A; Gabrielloni G; Milella D; Montesi M; Morcellini R; Parri G; Recanatini E; Beatrici V
Arch Ital Urol Androl; 2017 Mar; 89(1):39-41. PubMed ID: 28403596
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
Das S; Gu L; Eve CT; Parrish J; De Hoedt AM; McKee C; Aronson W; Freedland SJ; Williams SB
Clin Genitourin Cancer; 2023 Dec; 21(6):711.e1-711.e6. PubMed ID: 37198099
[TBL] [Abstract][Full Text] [Related]
9. A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.
Lapini A; Minervini A; Masala A; Schips L; Pycha A; Cindolo L; Giannella R; Martini T; Vittori G; Zani D; Bellomo F; Cosciani Cunico S
Surg Endosc; 2012 Dec; 26(12):3634-41. PubMed ID: 22729704
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.
Pietzak EJ
Curr Urol Rep; 2017 May; 18(5):39. PubMed ID: 28324275
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesions.
Bazargani ST; Djaladat H; Schuckman AK; Hugen CM; Daneshmand S
Videourology (New Rochelle); 2018; 32(2):. PubMed ID: 31976152
[No Abstract] [Full Text] [Related]
12. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.
Lotan Y; Inman BA; Davis LG; Kassouf W; Messing E; Daneshmand S; Canter D; Marble HT; Joseph AM; Jewell S; Boorjian SA
J Urol; 2019 Nov; 202(5):920-926. PubMed ID: 31120373
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.
Pederzoli F; Murati Amador B; Samarska I; Lombardo KA; Kates M; Bivalacqua TJ; Matoso A
Hum Pathol; 2019 Aug; 90():1-7. PubMed ID: 31071342
[TBL] [Abstract][Full Text] [Related]
14. [Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].
Abascal Junquera JM; Hevia Suárez M; Abascal García JM; Estébanez C; Astudillo A; Abascal R
Arch Esp Urol; 2008 May; 61(4):475-82; discussion 482-3. PubMed ID: 18592765
[TBL] [Abstract][Full Text] [Related]
15. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.
Williams SB; Gavaghan MB; Fernandez A; Daneshmand S; Kamat AM
Urol Oncol; 2022 Jan; 40(1):10.e7-10.e12. PubMed ID: 34158205
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis.
Sari Motlagh R; Ghoreifi A; Yanagisawa T; Kawada T; Ahyai S; Merseburger AS; Abufaraj M; Abern M; Djaladat H; Daneshmand S; Shariat SF
BJU Int; 2024 Apr; ():. PubMed ID: 38658172
[TBL] [Abstract][Full Text] [Related]
17. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
Holmäng S; Ströck V
Eur Urol; 2012 Mar; 61(3):503-7. PubMed ID: 22119022
[TBL] [Abstract][Full Text] [Related]
18. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies.
Kamat AM; Willis DL; Dickstein RJ; Anderson R; Nogueras-González G; Katz RL; Wu X; Barton Grossman H; Dinney CP
BJU Int; 2016 May; 117(5):754-60. PubMed ID: 26032953
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y; Chaplin I; Ahmadi H; Meng X; Roberts S; Ladi-Seyedian S; Bagrodia A; Margulis V; Woldu S; Daneshmand S
BJU Int; 2021 Jan; 127(1):108-113. PubMed ID: 32648957
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
Pagliarulo V; Alba S; Gallone MF; Di Stasi S; Cormio L; Petitti T; Buscarini M; Minafra P; Carrieri G
J Endourol; 2017 Apr; 31(4):405-411. PubMed ID: 28145751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
